Brian Willis
Acute Care · Schaumburg, ILNPI 1770363178
Payments from drug & device makers
Across 57 payments — averaging $25.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$284
- Sequel Med Tech, LLC$139
- Lilly USA, LLC$138
- Medtronic$90
- Amneal Pharmaceuticals LLC$69
- Boehringer Ingelheim$68
- plus $675 from 18 others
What the payments were for
- Food & beverage$1,463100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 7 | $284 |
| Sequel Med Tech, LLC | 1 | $139 |
| Lilly USA, LLC | 9 | $138 |
| Medtronic | 3 | $90 |
| Amneal Pharmaceuticals LLC | 3 | $69 |
| Boehringer Ingelheim | 3 | $68 |
| Tandem Diabetes Care, Inc. | 4 | $64 |
| Corcept Therapeutics | 2 | $59 |
| Insulet Corporation | 2 | $51 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| Kyowa Kirin, Inc. | 2 | $47 |
| AbbVie | 2 | $47 |
| BETA Bionics, Inc. | 2 | $45 |
| Novo Nordisk | 2 | $42 |
| Amgen | 2 | $42 |
| Antares Pharma, Inc. | 2 | $35 |
| Mannkind Corporation | 2 | $35 |
| Bayer | 1 | $34 |
| AstraZeneca | 1 | $32 |
| Ascensia Diabetes Care US Inc. | 1 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Radius Health, Inc. | 1 | $18 |
| Amphastar Pharmaceuticals, Inc. | 1 | $14 |
| Theracosbio, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TWIIST$139
How this compares
$1,463 in reported general payments places this provider in the 80th percentile of 461 acute care providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 81 | $119,527 |
| OzempicSemaglutide | 32 | $51,117 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $35,032 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 14 | $33,008 |
| JardianceEmpagliflozin | 25 | $31,372 |
| TrulicityDulaglutide | 22 | $30,263 |
| JanuviaSitagliptin Phosphate | 11 | $17,997 |
| FarxigaDapagliflozin Propanediol | 17 | $17,344 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $14,886 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $9,436 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 45 | $7,950 |
| Humalog Kwikpen U-100Insulin Lispro | 23 | $7,324 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $5,695 |
| Novolog FlexpenInsulin Aspart | 15 | $4,893 |
| SynthroidLevothyroxine Sodium | 18 | $2,327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $138 | $149,790103 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $42 | $84,12646 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $22 | $35,03221 claims |
| Boehringer IngelheimJardiance | $68 | $31,37225 claims |
| AstraZenecaFarxiga | $32 | $17,34417 claims |
| AbbVieSynthroid | $47 | $2,32718 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $69 | $1,12591 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 461 acute care providers in Illinois.
Other acute care in Schaumburg
- Tedra GrayChicago$78K
- Lynn HickmanArlington Heights$61K
- Gwen CassidyChicago$46K
- Laura CoyleOak Lawn$34K
- Erin DarguzasChicago$17K
- Amy BatesQuincy$14K
- Sarah MiyataChicago$11K
- Katie MeadorChicago$10K
- Dena PelletreauArlington Heights$9K
- Pamela KontosHazel Crest$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.